S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ALDX Aldeyra Therapeutics Inc

4.20

0.26 (6.60%)

May 01 2024 - Closed

Delayed by 15 minutes

Aldeyra says dry eye disease study for reproxalap did not meet main goal

To read the full story on Seeking Alpha, click here.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics Inc News

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Thursday 25 April 2024 (7 days ago) • Business Wire

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Thursday 18 April 2024 (2 weeks ago) • Business Wire

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Thursday 28 March 2024 (1 month ago) • Business Wire

Form S-3 - Registration statement under Securities Act of 1933
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Tuesday 6 February 2024 (3 months ago) • Business Wire

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Monday 29 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Thursday 4 January 2024 (4 months ago) • Business Wire

Form 8-K - Current report
Thursday 21 December 2023 (4 months ago) • Edgar (US Regulatory)

More Aldeyra Therapeutics Inc News Articles

Global Developments (PK)

FBEC Worldwide (PK)

Mullen Automotive

Atacama Resources (PK)

NaturalShrimp (QB)

NioCorp Developments

Branded Legacy (PK)

International Star (PK)

MicroCloud Hologram

Fannie Mae (QB)

Tonner One World (PK)

Moon Equity (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions